Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 13/20 | 0.51 |
| ▸ | GABRD | O14764 | 13/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 13/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 13/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 13/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 13/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 13/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 13/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 13/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 13/20 | 0.51 |
| ▸ | GABRA4 | P48169 | 13/20 | 0.51 |
| ▸ | GABRE | P78334 | 13/20 | 0.51 |
| ▸ | GABRA6 | Q16445 | 13/20 | 0.51 |
| ▸ | GABRG1 | Q8N1C3 | 13/20 | 0.51 |
| ▸ | GABRG3 | Q99928 | 13/20 | 0.51 |
| ▸ | GABRQ | Q9UN88 | 13/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29171533 | 0.83 | MAPT (0.52) | TP53CYP3A4MAPTMAPK1CSNK2A2 | |
| SCHEMBL8715608 | 0.83 | GABRP (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3601132 | 0.80 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29160475 | 0.78 | TTR (0.49) | TP53MAPT | |
| SCHEMBL30770821 | 0.78 | THRB (0.42) | CYP3A4MAPTPIM1 | |
| SCHEMBL13978681 | 0.74 | TP53 (0.61) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL24714304 | 0.74 | CCNE2 (0.35) | CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL29826764 | 0.73 | MAOB (0.42) | MAPTMAPK1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL23887366 | 0.72 | LOXL2 (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5225235 | 0.71 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674823-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-20070238729-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-7226918-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| US-20040192687-A1 | Dna-pk inhibitors | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
| EP-1417196-A1 | DNA-PK INHIBITORS | Cancer Research Technology Limited (GB) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003024949-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192687-A1 | Dna-pk inhibitors | ATM, CHEK1, XRCC6 | GABRP 2802/4885GABRD 3853/4885GABRA1 4036/4885 |
| US-20070238729-A1 | DNA-PK INHIBITORS | ATM, CHEK2, CHEK1 | GABRP 3036/4885GABRD 4282/4885GABRA1 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.